- 10:28 AM Financial stability, climate change top on EU Prez...
- 10:27 AM UK joins G20 push for world levy on banks
- 10:27 AM Britain urges divided G20 to reach climate finance...
- 10:27 AM G20 leaders meet, talk about climate change, world...
- 06:47 PM 'The Sensex will test 14,500 at some point…'
- 04:16 PM See scope for more int'l listings of Indian cos: N...
- 04:12 PM Dollar weakness will boost EMs, commodities ahead:...
- 04:07 PM 'India would've grown at 7% had monsoon not played...
- 03:04 PM Bye-bye Circular 23!
- 03:00 PM CavinKare eyes Rs 100cr revenues from restaurant b...
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the company’s Abbreviated New Drug Application (ANDA) to market its generic version of Wyeth’s Protonix ®, pantoprazole tablets.
These generic pantoprazole tablets are AB-rated equivalent of Wyeth’s Protonix ® Delayed Release Tablets and include two strengths: 20 mg (base) and 40 mg (base). These strengths of Protonix® have annual sales of approximately USD 2.3 billion in the US.
Sun Pharma, being one of the first-to-file an ANDA for generic Protonix® with a para IV certification, shares a 180-day marketing exclusivity.
Pantoprazole is indicated for short term treatment of erosive esophagitis associated with GERD, maintenance of healing of erosive esophagitis and for treatment of hypersecretory conditions.
The Company is currently evaluating its launch options.
PROTONIX ® is a registered trademark of Wyeth Pharmaceuticals Inc
Sourced From: Sun Pharmaceutical Industries Ltd
|
|
Today's Special Column
with Kishore Biyani
Future Group and the MD of Pantaloon Retail (India) Limited , Group CEO
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- 'The Sensex will test 14,500 at some point…'
- Exit Suzlon Energy at Rs 83: Joshi
- Mahindra Satyam restarts hirings, recalls bench
- 'Bullish' Mark Mobius unfazed by recent market correction
- Sensex ends week 262 pts up, sectors to look at ahead
- SBI cuts deposit rates on slow credit, liquidity glut
- 'The Sensex will test 14,500 at some point…'
Source: CNBC-TV18
- See scope for more int'l listings of Indian cos: NYSE
Source: CNBC-TV18
- Dollar weakness will boost EMs, commodities ahead: HSBC
Source: CNBC-TV18
- 'India would've grown at 7% had monsoon not played truant'
Source: CNBC-TV18
- SBI cuts deposit rates on slow credit, liquidity glut
Source: Business Line
- Aurobindo drug gets US nod
Source: Business Line
- BEML bags Rs 185 cr NCL order
Source: Business Line
- Tatas going global with low-cost housing
Source: Business Line
